Literature DB >> 3037576

Malignant clear-cell hidradenoma.

L F Lopez-Burbano, G A Cimorra, E Gonzalez-Peirona, J Alfaro.   

Abstract

In this paper the authors present a case of malignant clear-cell hidradenoma developed on the dorsum of the hand. This is only the eleventh complete report in the literature, including follow-up, and only the third to include necropsy. It is the first to find both lung and myocardial metastases. The tumor was very invasive and was treated first by wide surgical excision and radical node dissection, and when the tumor recurred, amputation of the arm was done. The world literature was carefully reviewed and compared with this case. Owing to the already known failure of radiotherapy, and since chemotherapy was not successful in our patient, the authors advise early aggressive surgery, including block dissection of the regional nodes, and thereafter a careful follow-up.

Entities:  

Mesh:

Year:  1987        PMID: 3037576     DOI: 10.1097/00006534-198708000-00027

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  4 in total

1.  Diagnosis and treatment of clear cell hidradenocarcinoma of the scalp.

Authors:  Kai Shu; Qungen Xiao; Fabian Büchele; Suojun Zhang; Wei Jiang; Ting Lei
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-12-28

Review 2.  Clear cell hidradenocarcinoma of the eyelid: a case report with a review of the literature.

Authors:  Gurcharan Singh; Aparna Narasimha; Harendra Kumar; Narendra Datti
Journal:  Int Ophthalmol       Date:  2012-10-07       Impact factor: 2.031

Review 3.  Current management approach to hidradenocarcinoma: a comprehensive review of the literature.

Authors:  Abhishek Soni; Nupur Bansal; Vivek Kaushal; Ashok Kr Chauhan
Journal:  Ecancermedicalscience       Date:  2015-03-19

4.  Malignant acrospiroma: a case report in the era of next generation sequencing.

Authors:  Maria Diab; Ali Gabali; Muaiad Kittaneh
Journal:  BMC Cancer       Date:  2017-03-27       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.